| Epizyme Collaborates with Celgene to Develop Epigenetics-Based Targeted Cancer Therapeutics |
Abstract
|
|
Heather Cartwright |
|
| Start-Up Tolero Pharmaceuticals Licenses MannKind’s Btk Programme in US$130 M Deal |
Abstract
|
|
Heather Cartwright |
|
| ASLAN Pharmaceuticals Gains Third Pipeline Drug via Licensing Deal with Almirall |
Abstract
|
|
Heather Cartwright |
|
| Amgen Forays into Turkish Generics Market with MN Pharmaceuticals Purchase |
Abstract
|
|
Heather Cartwright |
|
| Watson to Become World’s Third Largest Generics Company with US$5.9 B Actavis Buyout |
Abstract
|
|
Heather Cartwright |
|
| Jazz Pharmaceuticals Diversifies into Oncology with EUSA Pharma Purchase |
Abstract
|
|
Heather Cartwright |
|
| Novartis’ Sandoz to Become Largest Generic Dermatology Company with US$1.53 B Fougera Pharmaceuticals Acquisition |
Abstract
|
|
Heather Cartwright |
|
| Abbott to Acquire Global Rights to Action Pharma’s Phase II Acute Kidney Injury Drug |
Abstract
|
|
Heather Cartwright |
|
| GSK to Acquire Full Control of its Proteomics Partner Cellzome |
Abstract
|
|
Heather Cartwright |
|
| Agilent Technologies Agrees to Acquire Dako for US$2.2 B in its Largest Deal to Date |
Abstract
|
|
Heather Cartwright |
|
| InterMune Divests Declining Actimmune® to Focus on Esbriet® |
Abstract
|
|
Heather Cartwright |
|
| Takeda Aims for Globalisation with Purchase of Brazilian Company Multilab |
Abstract
|
|
Heather Cartwright |
|
